Dr. Shallis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Phone+1 813-745-7365Fax+1 813-449-8618
Education & Training
- Rutgers Robert Wood Johnson Medical SchoolClass of 2014
Certifications & Licensure
- FL State Medical License 2025 - 2027
- CT State Medical License 2017 - 2025
- RI State Medical License 2014 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Start of enrollment: 2023 Jun 27
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.Alexandra E Rojek, Benjamin J McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza
American Journal of Hematology. 2025-03-10 - NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand
Journal of the National Comprehensive Cancer Network. 2025-03-01 - Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan
Leukemia & Lymphoma. 2025-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: